Vaxxa levererade omsättningstillväxt i det fjärde kvartalet.
Nettoomsättningen i Q4’25 uppgick till 152,8 MNOK (80,1), motsvarande en tillväxt om 90,8 %.
Today, trading in Train Alliance shares has been temporarily suspended.
Gofore just announced (via a stock exchange release) it has been chosen as the priority supplier for...
Redeye raises its forecasts and Base Case slightly following the acquisition of JOWO, strengthening ...
Redeye provides an update following MindArk’s Q4 2025 report, which showed weaker than anticipated s...
Redeye positively views the FDA approval of extended labelling for Nevisense, allowing measurements ...
CapMan just announced its second exit from its Infra I fund (2020).
Nokian Panimo delivered a solid H2 in line with expectations, entering 2026 with a record product la...
Xplora reported record results in the Q4 report, and it reported gross profit of NOK 312m, 7% higher...
mResell levererade 131 % intäktstillväxt i Q4’25 trots en temporär regulatorisk påverkan.
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust i det fjärde kva...
Hanza redovisade ett starkt bokslut för 2025 med rekordhög marginal.
Redeye returns with an update following Guldbrev's mixed Q4 report that posted stronger growth than ...
Redeye comments on MindArk’s Q4 results, which came in somewhat softer than expected.
Redeye provides its initial take on Heliospectra’s Q4 results, which showed softer-than-expected fig...
Redeye provides an initial take following Paxman’s Q4 2025 report.
Physitracks Q4 results aligned with its preliminary figures, highlighted by continued margin expansi...
Redeye views Xplora's Q4 2025 results positively despite a miss against its own forecasts, as the pr...
With key trials successfully initiated and the balance sheet strengthened in 2025, Curasight is set ...